Teresa Corona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6856975/publications.pdf

Version: 2024-02-01

112 3,817 30 papers citations h-index

126 126 126 5408 all docs docs citations times ranked citing authors

57

g-index

#	Article	IF	CITATIONS
1	Variantes del gen ABCB1 como factores de riesgo y factores moduladores de la edad de inicio en pacientes mexicanos con enfermedad desmielinizante. NeurologÃa, 2023, 38, 65-74.	0.3	2
2	Onychomycosis Caused by <i>Kloeckera apiculata</i> : A Case Report in a Patient with Multiple Sclerosis. Skin Appendage Disorders, 2022, 8, 1-4.	0.5	2
3	Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma. Cellular and Molecular Neurobiology, 2021, 41, 1285-1297.	1.7	5
4	Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of glioblastoma. Neuro-Oncology, 2021, 23, 599-610.	0.6	23
5	Onychomycosis in patients with multiple sclerosis: prevalence, clinical description, mycological, and dermoscopic study in a Mexican population. International Journal of Dermatology, 2021, 60, 1102-1108.	0.5	O
6	Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico. Multiple Sclerosis and Related Disorders, 2021, 52, 103022.	0.9	4
7	Interaction of HLA Class II rs9272219 and TMPO rs17028450 (Arg690Cys) Variants Affects Neuromyelitis Optica Spectrum Disorder Susceptibility in an Admixed Mexican Population. Frontiers in Genetics, 2021, 12, 647343.	1.1	2
8	Herpes viruses in optic neuritis: Similar to Bell's palsy. Clinical Neurology and Neurosurgery, 2020, 188, 105588.	0.6	4
9	Antiâ€aquaporinâ€4 antibodyâ€positive neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis. Clinical and Experimental Neuroimmunology, 2020, 11, 40-44.	0.5	О
10	Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093616.	1.5	58
11	Journal Club: Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology, 2020, 95, 701-704.	1.5	O
12	Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population. Scientific Reports, 2020, 10, 13706.	1.6	18
13	Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México. Journal of the Neurological Sciences, 2020, 419, 117204.	0.3	9
14	Involuntary Emotional Expression Disorder in a Patient With Toluene Leukoencephalopathy. Revista Colombiana De PsiquiatrÁa, 2020, , .	0.1	0
15	Independence of Coping Styles With the Patient–Doctor Relationship and Shared Decision-Making in People With Parkinson's Disease. Journal of Patient Experience, 2020, 7, 1271-1277.	0.4	2
16	AQP4-IgG-positive neuromyelitis optica spectrum disorder with late onset in Mexico Multiple Sclerosis and Related Disorders, 2020, 43, 102221.	0.9	5
17	Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder. Clinical Neurology and Neurosurgery, 2020, 196, 106007.	0.6	3
18	Stoichiometric Formation of an Oxoiron(IV) Complex by a Soluble Methane Monooxygenase Type Activation of O ₂ at an Iron(II)-Cyclam Center. Journal of the American Chemical Society, 2020, 142, 5924-5928.	6.6	27

#	Article	IF	CITATIONS
19	Diversity of HLA Class I and Class II blocks and conserved extended haplotypes in Lacandon Mayans. Scientific Reports, 2020, 10, 3248.	1.6	11
20	Palatal tremor and intact Guillainâ∈Mollaret triangle secondary to Hashimotoâ∈™s encephalopathy. Clinical and Experimental Neuroimmunology, 2020, 11, 192-195.	0.5	0
21	Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation. Nature Communications, 2020, 11, 1747.	5.8	85
22	Manifestaciones neurol \tilde{A}^3 gicas en la enfermedad del coronavirus 2019. Gaceta Medica De Mexico, 2020, 156, 317-320.	0.5	3
23	Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic. Gaceta Medica De Mexico, 2020, 156, 478-480.	0.5	O
24	The monetary burden of cysticercosis in Mexico. PLoS Neglected Tropical Diseases, 2019, 13, e0007501.	1.3	19
25	Air Pollution, Multiple Sclerosis and its Relevance to Mexico City. Archives of Medical Research, 2019, 50, 111-112.	1.5	11
26	Quality of life in patients with multiple sclerosis and its association with depressive symptoms and physical disability. Multiple Sclerosis and Related Disorders, 2019, 36, 101386.	0.9	45
27	Trapping of a Highly Reactive Oxoiron(IV) Complex in the Catalytic Epoxidation of Olefins by Hydrogen Peroxide. Angewandte Chemie - International Edition, 2019, 58, 4012-4016.	7.2	41
28	Highly Selective and Catalytic Oxygenations of Câ^'H and C=C Bonds by a Mononuclear Nonheme Highâ€Spin Iron(III)â€Alkylperoxo Species. Angewandte Chemie - International Edition, 2019, 58, 12534-12539.	7.2	8
29	Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells. ASN Neuro, 2019, 11, 175909141983244.	1.5	10
30	Heme and Nonheme High-Valent Iron and Manganese Oxo Cores in Biological and Abiological Oxidation Reactions. ACS Central Science, 2019, 5, 13-28.	5.3	275
31	Letter to the Editor. Revista De Investigacion Clinica, 2019, 71, 142.	0.2	O
32	Histopathology and Antibodies. Vascular and Endovascular Surgery, 2018, 52, 237-237.	0.3	0
33	Water Oxidation Reaction Mediated by an Octanuclear Ironâ€Oxo Cluster. European Journal of Inorganic Chemistry, 2018, 2018, 4930-4931.	1.0	1
34	Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma. PLoS ONE, 2018, 13, e0206590.	1.1	13
35	Nucleophilic versus Electrophilic Reactivity of Bioinspired Superoxido Nickel(II) Complexes. Angewandte Chemie - International Edition, 2018, 57, 14883-14887.	7.2	18
36	Pre-hospitalization, hospitalization, and post-hospitalization costs of patients with neurocysticercosis treated at the Instituto Nacional de Neurologia y Neurocirugia (INNN) in Mexico City, Mexico. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2018, 60, e20.	0.5	3

#	Article	IF	CITATIONS
37	Water Oxidation Reaction Mediated by an Octanuclear Ironâ€Oxo Cluster. European Journal of Inorganic Chemistry, 2018, 2018, 4925-4929.	1.0	12
38	Epigenetics in Multiple Sclerosis: Molecular Mechanisms and Dietary Intervention. Central Nervous System Agents in Medicinal Chemistry, 2018, 18, 8-15.	0.5	9
39	Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences. Central Nervous System Agents in Medicinal Chemistry, 2018, 18, 4-7.	0.5	31
40	Time until relapse after augmentation with singleâ€dose ketamine in treatmentâ€resistant depression. Psychiatry and Clinical Neurosciences, 2018, 72, 623-623.	1.0	5
41	Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2018, 25, 268-270.	0.9	13
42	Vitamin D and disability in relapsing–remitting multiple sclerosis in patients with a Mexican background. Acta Neurologica Belgica, 2018, 118, 47-52.	0.5	15
43	Phenotypic Variability in a Mexican Mestizo Family with Retinal Vasculopathy with Cerebral Leukodystrophy and TREX1 Mutation p.V235Gfs*6. Revista De Investigacion Clinica, 2018, 70, 68-75.	0.2	7
44	Activation of Dioxygen at a Lewis Acidic Nickel(II) Complex: Characterization of a Metastable Organoperoxide Complex. Angewandte Chemie - International Edition, 2017, 56, 2307-2311.	7.2	36
45	CLUH regulates mitochondrial metabolism by controlling translation and decay of target mRNAs. Journal of Cell Biology, 2017, 216, 675-693.	2.3	73
46	Cigarette Smoking, Alcohol Consumption and Overweight in Multiple Sclerosis: Disability Progression. Archives of Medical Research, 2017, 48, 113-120.	1.5	26
47	Trapping of superoxido cobalt and peroxido dicobalt species formed reversibly from Co ^{II} and O ₂ . Chemical Communications, 2017, 53, 11782-11785.	2.2	33
48	Who Can Diagnose Parkinson's Disease First? Role of Pre-motor Symptoms. Archives of Medical Research, 2017, 48, 221-227.	1.5	22
49	lgG4-related disease and lgG4-mediated neurological autoimmune disorders: One and the same?. Journal of Neuroimmunology, 2017, 310, 129-130.	1.1	0
50	Neuropsychiatric disorders in patients with neurocysticercosis. Asia-Pacific Psychiatry, 2017, 9, e12250.	1.2	6
51	Niños en cuerpos de adultos. Salud Publica De Mexico, 2017, 59, 488.	0.1	0
52	The genetics of multiple sclerosis in Latin America. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772729.	0.5	4
53	Clinical prognostic factors in adults with astrocytoma: Historic cohort. Clinical Neurology and Neurosurgery, 2016, 146, 116-122.	0.6	24
54	Rapid Hydrogen and Oxygen Atom Transfer by a High-Valent Nickel–Oxygen Species. Journal of the American Chemical Society, 2016, 138, 12987-12996.	6.6	66

#	Article	IF	CITATIONS
55	Characterization and Reactivity Studies of a Terminal Copper–Nitrene Species. Angewandte Chemie - International Edition, 2016, 55, 14005-14008.	7.2	33
56	Spectroscopically Characterized Synthetic Mononuclear Nickel–Oxygen Species. Chemistry - A European Journal, 2016, 22, 13422-13429.	1.7	42
57	Nitrous oxide activation by a cobalt(<scp>ii</scp>) complex for aldehyde oxidation under mild conditions. Dalton Transactions, 2016, 45, 14530-14533.	1.6	17
58	NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF- $\hat{\mathbb{I}}^2$ B-Dependent and -Independent Functions. Immunity, 2016, 44, 553-567.	6.6	157
59	Vitamin D in multiple sclerosis patients: Not the same risk for everybody. Multiple Sclerosis Journal, 2016, 22, 126-127.	1.4	9
60	Reactivity of a Nickel(II) Bis(amidate) Complex with <i>meta</i> 倀hloroperbenzoic Acid: Formation of a Potent Oxidizing Species. Chemistry - A European Journal, 2015, 21, 15029-15038.	1.7	82
61	Catatonia and Klýver-Bucy Syndrome in a Patient With Acute Disseminated Encephalomyelitis. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, e161-e162.	0.9	4
62	Hypothyroidism in multiple sclerosis patient during fingolimod treatment. Journal of the Neurological Sciences, 2015, 348, 272-273.	0.3	3
63	Cost of neurocysticercosis patients treated in two referral hospitals in <scp>M</scp> exico <scp>C</scp> ity, <scp>M</scp> exico. Tropical Medicine and International Health, 2015, 20, 1108-1119.	1.0	11
64	Presence of the HLADR13 allele among Mexican Mestizos suggests a protective factor against relapsing-remitting multiple sclerosis (RRMS). Clinical Neurology and Neurosurgery, 2015, 138, 184-187.	0.6	3
65	<i>CYP2D6</i> genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas. Pharmacogenomics, 2014, 15, 1859-1865.	0.6	13
66	Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: Results of the RELACCEM study. Multiple Sclerosis and Related Disorders, 2014, 3, 335-340.	0.9	16
67	Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization. Journal of the Neurological Sciences, 2014, 339, 196-206.	0.3	24
68	RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature, 2014, 513, 90-94.	13.7	439
69	Assessing the Impact of Electronic and Steric Tuning of the Ligand in the Spin State and Catalytic Oxidation Ability of the Fe ^{II} (Pytacn) Family of Complexes. Inorganic Chemistry, 2013, 52, 9229-9244.	1.9	102
70	Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson's Disease. Archives of Medical Research, 2013, 44, 110-114.	1.5	25
71	Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson's disease. Neurological Sciences, 2013, 34, 979-983.	0.9	7
72	The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. Multiple Sclerosis Journal, 2013, 19, 844-854.	1.4	62

#	Article	IF	Citations
73	The Economic Impact of Smoking on the Treatment Costs of Stroke at a Tertiary Care Neurological Center in Mexico. International Journal of Stroke, 2013, 8, E23-E23.	2.9	1
74	Estimating the Non-Monetary Burden of Neurocysticercosis in Mexico. PLoS Neglected Tropical Diseases, 2012, 6, e1521.	1.3	61
75	Absence of Multiple Sclerosis and Demyelinating Diseases among Lacandonians, a Pure Amerindian Ethnic Group in Mexico. Multiple Sclerosis International, 2012, 2012, 1-4.	0.4	19
76	Vinpocetine Inhibits Oligodendroglial Precursor Cell Differentiation. Cellular Physiology and Biochemistry, 2012, 30, 711-722.	1.1	9
77	Overweight is more prevalent in patients with Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2012, 70, 843-846.	0.3	29
78	Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity, 2011, 44, 571-575.	1.2	20
79	Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis. Multiple Sclerosis International, 2011, 2011, 1-5.	0.4	13
80	Relación entre el tipo y lado de inicio de la sintomatologÃa motora con la frecuencia de sÃntomas no motores en la enfermedad de Parkinson. NeurologÃa, 2011, 26, 319-324.	0.3	9
81	Herpes Zoster and Multiple Sclerosis. Journal of Infectious Diseases, 2011, 204, 177-178.	1.9	3
82	Safety and tolerability of dapsone for the treatment of patients with drug-resistant, partial-onset seizures: an open-label trial. Neurological Sciences, 2011, 32, 1063-1067.	0.9	10
83	Use of smell test identification in Parkinson's disease in Mexico: A matched caseâ€control study. Movement Disorders, 2011, 26, 173-176.	2.2	22
84	Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Review of Anti-Infective Therapy, 2011, 9, 123-133.	2.0	135
85	Quality of Life in Patients with Neurocysticercosis in Mexico. American Journal of Tropical Medicine and Hygiene, 2011, 84, 782-786.	0.6	28
86	Mental Disorders in Mexican Patients With Multiple Sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 63-69.	0.9	21
87	Non-Cooperative Interactions Between Transcription Factors and Clustered DNA Binding Sites Enable Graded Transcriptional Responses To Environmental Inputs. Biophysical Journal, 2010, 98, 68a.	0.2	0
88	Noncooperative Interactions between Transcription Factors and Clustered DNA Binding Sites Enable Graded Transcriptional Responses to Environmental Inputs. Molecular Cell, 2010, 37, 418-428.	4.5	155
89	Varicella zoster virus in progressive forms of multiple sclerosis. Clinical Neurology and Neurosurgery, 2010, 112, 653-657.	0.6	23
90	Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City. Clinical Neurology and Neurosurgery, 2010, 112, 883-885.	0.6	23

#	Article	IF	Citations
91	Epilepsy and multiple sclerosis: Increased risk among progressive forms. Epilepsy Research, 2009, 84, 250-253.	0.8	32
92	Association of a history of varicella virus infection with multiple sclerosis. Clinical Neurology and Neurosurgery, 2009, 111, 54-56.	0.6	28
93	Lipid peroxidation in the cerebrospinal fluid of patients with neurocysticercosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 1025-1031.	0.7	5
94	Multiple Sclerosis in Latin America. Neuroepidemiology, 2006, 26, 1-3.	1.1	54
95	Severe impulsiveness as the primary manifestation of multiple sclerosis in a young female. Psychiatry and Clinical Neurosciences, 2005, 59, 739-742.	1.0	17
96	Mediterranean and Amerindian MHC class II alleles are associated with multiple sclerosis in Mexicans. Acta Neurologica Scandinavica, 2005, 112, 317-322.	1.0	25
97	Is dementia reversible in patients with neurocysticercosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1164-1166.	0.9	49
98	Sleep disturbances, socioeconomic status, and seizure control as main predictors of quality of life in epilepsy. Epilepsy and Behavior, 2005, 7, 481-485.	0.9	112
99	Calcific neurocysticercosis and epileptogenesis. Neurology, 2004, 62, 1934-1938.	1.5	228
100	Improving the Autopsy Rate in a Teaching Hospital. Archives of Pathology and Laboratory Medicine, 2003, 127, 1408-1409.	1.2	2
101	Optimization of the single-day praziquantel therapy for neurocysticercosis. Neurology, 2001, 57, 1929-1929.	1.5	25
102	Possible association between Taenia solium cysticercosis and cancer: increased frequency of DNA damage in peripheral lymphocytes from neurocysticercosis patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 61-65.	0.7	35
103	Cardiovascular dysfunction inmultiple sclerosis. Acta Neurologica Scandinavica, 2000, 101, 85-88.	1.0	94
104	Severe anaphylaxis with recombinant interferon beta. Neurology, 1999, 52, 425.	1.5	33
105	Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrobial Agents and Chemotherapy, 1997, 41, 1256-1259.	1.4	59
106	Optic neuritis progressing to multiple sclerosis. Acta Neurologica Scandinavica, 1997, 95, 85-89.	1.0	19
107	Single-Day Praziquantel Therapy for Neurocysticercosis. New England Journal of Medicine, 1996, 334, 125-125.	13.9	52
108	A Longitudinal Study of the Effects of an L-dopa Drug Holiday on the Course of Parkinson $\hat{E}^{1}/4$ s Disease. Clinical Neuropharmacology, 1995, 18, 325-332.	0.2	16

#	Article	IF	CITATION
109	Humoral immune response in patients with cerebral parenchymal cysticercosis treated with praziquantel Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 254-257.	0.9	19
110	Anticysticercous antibodies in serum and cerebrospinal fluid in patients with cerebral cysticercosis Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 1044-1049.	0.9	44
111	A prognostic classification of cerebral cysticercosis: therapeutic implications Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 1131-1134.	0.9	92
112	Diagnosis of reversible versus irreversible cerebral ischemia by the intravenous administration of naloxone Stroke, 1985, 16, 1006-1009.	1.0	17